The rapid emergence of oral nicotine pouches has presented policymakers with a familiar challenge. Innovation is moving faster than legislation, forcing regulators to determine how new products fit within legal frameworks that were largely designed for traditional tobacco products decades ago.
A recent editorial published in Addiction, “Novel Product, Familiar Challenges: Navigating Uncertainty in Oral Nicotine Pouch Regulation,” argues that oral nicotine pouches (ONPs) currently occupy a legal grey area in many jurisdictions. The authors suggest that governments should move beyond ambiguity by explicitly addressing nicotine pouches in legislation rather than relying on courts to interpret laws written before these products existed.
This is an important observation.
As nicotine products continue to evolve, governments face increasing pressure to ensure that regulatory frameworks remain clear, predictable, and capable of responding to innovation. Legal ambiguity benefits no one. It creates uncertainty for regulators, manufacturers, retailers, healthcare professionals, and consumers alike while increasing the likelihood of inconsistent enforcement and prolonged legal disputes.
However, legal certainty alone should not become the primary objective. Just as importantly, regulatory frameworks should reflect the best available scientific evidence and remain proportionate to the risks presented by different nicotine products.
Innovation Is Challenging Regulatory Frameworks
The editorial notes that nicotine pouches present unique challenges because they do not fit neatly within traditional tobacco legislation. Some products contain tobacco-derived nicotine, others contain synthetic nicotine, and many definitions embedded within existing laws continue to rely on concepts developed for combustible tobacco or products containing tobacco leaf.
This is not the first time policymakers have encountered such a situation.
When electronic cigarettes entered international markets more than a decade ago, many jurisdictions faced similar uncertainty. Existing legislation frequently failed to anticipate products that delivered nicotine without burning tobacco. The result was fragmented regulation, inconsistent enforcement, and numerous legal disputes over how existing laws should be interpreted.
The Addiction editorial argues that governments should avoid repeating this experience by updating legislation proactively rather than relying on judicial interpretation to fill legislative gaps.
That lesson extends beyond nicotine pouches. Regulatory systems should be sufficiently flexible to accommodate future innovations without requiring courts to determine legislative intent each time a new product category emerges.
Legal Clarity Should Not Mean Regulatory Uniformity
Providing legal certainty, however, is only part of the regulatory challenge.
Equally important is determining whether different nicotine products should be regulated identically or whether regulatory requirements should reflect differences in product characteristics and risk.
Scientific understanding has evolved considerably over the past two decades. Today, there is broad recognition that the overwhelming majority of smoking-related disease results from exposure to the toxic products of combustion rather than nicotine itself. This distinction has become central to discussions surrounding tobacco harm reduction and the continuum of risk among nicotine products.
Although nicotine pouches are not risk-free and should remain subject to appropriate regulatory oversight, they differ substantially from combustible cigarettes in both composition and mode of use.
For this reason, simply placing all nicotine products into a single regulatory category may provide administrative simplicity but does not necessarily reflect the current scientific understanding of relative risk.
Risk-proportionate regulation does not imply weaker regulation. Rather, it seeks to ensure that regulatory requirements remain appropriate to the characteristics of individual products while continuing to prioritise public health objectives, youth protection, product safety, and consumer information.
Good Regulation Should Anticipate Innovation
One of the strongest messages from the editorial is that legislation should become more forward-looking.
The authors recommend that governments regularly review tobacco and nicotine legislation, establish mechanisms to identify emerging regulatory gaps, and empower expert regulatory agencies to update technical guidance as markets evolve.
These recommendations recognise an important reality: legislation often moves more slowly than technological innovation.
Nicotine markets continue to diversify. Alongside traditional cigarettes are heated tobacco products, electronic cigarettes, oral nicotine pouches, synthetic nicotine products, and potentially nicotine analogues currently under development.
If legislation continues to be written only for products that already exist, governments will repeatedly encounter the same cycle of uncertainty each time innovation introduces a new category.
Future-ready regulation therefore requires legislation that focuses on product characteristics, public health objectives, and scientific evidence rather than relying solely on historic product definitions.
Lessons for the European Union
The issues identified in the editorial are particularly relevant for Europe.
The European Union is currently considering future revisions to the Tobacco Products Directive (TPD), while discussions also continue regarding the Tobacco Excise Directive (TED). Both legislative processes present opportunities to examine how nicotine products should be addressed within modern regulatory frameworks.
As the editorial notes, policymakers will inevitably need to determine whether oral nicotine pouches should be incorporated into future EU legislation and, if so, how they should be classified.
These decisions extend beyond legal definitions. They will influence product standards, consumer information requirements, market surveillance, taxation, enforcement, and ultimately public health outcomes across Member States.
The objective should therefore not simply be to ensure that nicotine pouches fit within existing legislation, but to ensure that any revised framework reflects contemporary scientific evidence while remaining sufficiently adaptable to accommodate future innovation.
Regulation Should Follow Evidence
For GINN, the discussion surrounding oral nicotine pouches illustrates a broader principle that applies across tobacco and nicotine policy.
Good regulation depends upon two complementary foundations.
The first is legal certainty. Clear statutory definitions reduce ambiguity, improve compliance, support effective enforcement, and minimise unnecessary litigation.
The second is scientific proportionality. Regulatory requirements should reflect the best available evidence concerning product characteristics, patterns of use, and public health impact, while remaining responsive as new evidence emerges.
These two principles are mutually reinforcing rather than mutually exclusive.
Clear legislation provides certainty.
Evidence-based regulation provides credibility.
Together they create regulatory systems capable of protecting public health while remaining sufficiently flexible to respond to scientific progress and technological innovation.
Looking Ahead
The publication of Novel Product, Familiar Challenges: Navigating Uncertainty in Oral Nicotine Pouch Regulation is a timely contribution to an increasingly important policy discussion. It highlights the practical consequences of legislative ambiguity and reminds policymakers that emerging nicotine products require frameworks designed for today’s marketplace rather than yesterday’s.
As governments around the world review tobacco and nicotine legislation, the challenge is not simply to determine whether nicotine pouches should be regulated. That question has largely been answered.
The more important question is how they should be regulated.
For GINN, the answer lies in combining legal clarity with evidence-based, risk-proportionate regulation. As scientific understanding continues to evolve, regulatory frameworks should evolve with it, ensuring that legislation remains clear, adaptable, and focused on achieving meaningful public health outcomes rather than relying on outdated statutory definitions alone.
Source
